Trials / Completed
CompletedNCT06662396
A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007)
A Study to Evaluate the Effects of Coadministration of Diltiazem on the Plasma Pharmacokinetics of a Single Dose of MK-6552 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main goal of this study is to learn what happens to MK-6552 in a person's body over time (a pharmacokinetic or PK study). Researchers want to know what happens to MK-6552 in healthy adults when a single dose of MK-6552 is given with multiple doses of diltiazem. The researchers believe that multiple doses of diltiazem will not affect the highest amount of MK-6552 in the blood.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-6552 | Oral Gelatin Coated Capsule |
| DRUG | Diltiazem | Oral Extended-Release Capsule |
Timeline
- Start date
- 2024-06-13
- Primary completion
- 2024-09-27
- Completion
- 2024-09-27
- First posted
- 2024-10-28
- Last updated
- 2024-10-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06662396. Inclusion in this directory is not an endorsement.